1Cell.Ai
OncoIndx™
NexGen Sequencing

NexGen Sequencing
for precision powered decisions

OncoIndx® offers comprehensive genomic profiling across solid tumors. Its unique design identifies key actionable insights for personalising cancer treatment.

OncoIndx® in practice

- Challenges of managing complex cancers are addressed through evidence-based treatment choice.
- NGS report enhanced with artificial intelligence and updated clinical studies help identify the most beneficial therapeutic options.
- An easy digital interface to interpret and understand complex cancer genomics.

Where is OncoIndx® needed?

- Cancers progressing on standard-of-care treatment.
- Cancers where personalised treatment could enhance survival.
- Cancers showing resistance to conventional treatment.
- Cancers where combination of target drugs and/or immunotherapy could benefit.

Clinical and Technical Validation of OncoIndx® Assay
A Comprehensive Genome Profiling Assay for Pan-Cancer investigations

Alteration	* PPV	* NPV	Accuracy	Specificity	Sensitivity
SNVs	100	100	100	100	100
Small INDELs	100	94.03	97.40	100	95.60
CNA	100	100	100	100	100
Fusions	100	96.43	98.48	100	97.44

* NPV: Negative predictive value. PPV: Positive predictive value.

Scan QR to read the full article

Designed for oncologists managing complex, advanced and refractory cancer patients.

- Proprietary panel of 1,000+ genes
- Longitudinal monitoring markers
- PD-L1 through IHC (TBx) / immunofluorescence on CTCs (LBx)
- CTC enumeration
- Traceability to ongoing clinical trials worldwide



Key Actionable Genes Include:

Lung
EGFR, ALK, HRAS, NRAS, KRAS, BRAF, TERT, ROS1, MET, RET, NTRK1/2/3, ERBB2,PIK3CA

Melanoma
BRAF, KIT, ROS1, NTRK1/2/3

Colorectal
BRAF, KRAS, NRAS, HRAS, ERBB2, MLH1, MSH2, MSH6, PMS2, NTRK1/2/3

Gastrointestinal
ALK, HRAS, HER2, NRAS, KRAS, BRAF, TERT, ROS1, MET, RET, NTRK1/2/3

Prostate
BRCA1, BRCA2, MLHl, MSH2, MSH6, PMS2, AR, NTRK1/2/3

Breast
BRCA1, BRCA2, HER2, PIK3CA, MSH6, PMS2,NTRK1/2/3,MLH1,BRAF

Bladder
FGFR2/3, NTRK1/2/3

Ovary
BRCA1, BRCA2, HER2, PMS2,MLH1, MSH2,MSH6, NTRK1/2/3

Thyroid
ALK, HRAS, NRAS, KRAS, BRAF, TERT, RET, NTRK1/2/3

Features of OncoIndx report

- In accordance to international guidelines.
- Clear, unambiguous and actionable genomic findings.
- Based on highly reliable and internally curated databases.

Techincal Specification

Specimen	Liquid (CSF, Plasma, Pleural Fluid)	Tissue
Panel Size	3 MB	3 MB
Sample Type	cfDNA (TagFlexLB/Norgen/PaxGene Tube) + 1 tube of 8.5 ml Peripheral Whole Blood (~8-10 days of washout period required if patient under therapy e.g., Chemotherapy, Radiation, Immunotherapy, etc.)	1 FFPE tissue block with 20-30 % tumor content (not more than 3-4 months old)*
Sample Collection	Peripheral blood using butterfly needles/ 22 gauge syringe	FFPE tissue block
Sample volume/quantity	8.5 ml (1 tube)	1 FFPE block with 20-30% tumor content
cfDNA/DNA input amount	> 1ng	> 1ng
Sequencing platform	Illumina	Illumina
Read Length	2 x 150bp	2 x 150bp
Mean Sequencing Depth	10000x	2000x
Sequencing Chemistry	Hybrid capture	Hybrid capture
Indications	Solid Tumor	Solid Tumor
Analysis and Reporting	iCare™- AI based analysis platform with active reporting options	

OncoIndx® is a well-validated NGS test to extract therapy information from tumor DNA. It is possible on both tissue as well as blood sample.

1000+ genes panel
This NGS test includes 1000+ genes of targetable/ therapeutic significance.

>99% on target coverage
The test has a mean coverage of 98-100% across all tested genes.

2000x / 10000x mean depth
The test is performed at a mean depth of 2000x for tissue samples and 10000x for blood.

1Cell.Ai™
Ai-Powered Precision Oncology

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

MC-7348

Learn More at 1Cell.Ai
Mail - info@1cell.ai | Tel - 1800 123 12355